Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgeries. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force in Europe, the Middle East, Africa, Latin …
Full ESTA analysis →
Competitive advantage assessment
Key strengths
Comfortable Interest CoverageInterest coverage quality is strong vs peers (score 0.68). Debt servicing capacity supports continued M&A optionality.
Establishment Labs Holdings Inc ranks #48 of 160
scored companies in Medical Devices by moat score — the top 30%.
The widest moat in the group is iRadimed Corporation (IRMD)
at 83/100.
Moat scores for companies ranked near ESTA in Medical Devices
How ESTA scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 73
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 56
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 62
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 62
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 39
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 49
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
What is Establishment Labs Holdings Inc's moat score?
Establishment Labs Holdings Inc (ESTA) scores 60 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #48 of 160 scored companies in Medical Devices, the top 30%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Pricing Power & Consumable Moat (73/100) and its weakest is Capital Structure & Resilience (39/100).
How does Establishment Labs Holdings Inc compare with other Medical Devices companies?
Establishment Labs Holdings Inc ranks #48 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are NovoCure Limited (NVCR) at 60 just above it and ZimVie Inc. (ZIMV) at 59 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.
Why is Establishment Labs Holdings Inc scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Establishment Labs Holdings Inc?
The Medical Devices & Diagnostics template measures 6 defenses, and ESTA scores: Pricing Power & Consumable Moat (73), R&D Pipeline & Capital Returns (56), FCF Quality & Cash Conversion (62), Commercial Execution (62), Capital Structure & Resilience (39), Growth Durability (49). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.